NCT04745806TerminatedNot Applicable
A Prospective, Single Arm, Post Marketing Study for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard to Heal Wounds
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- RedDress Ltd.
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- Percent of Reduction in Wound Size Over 12 Weeks
Study Overview
Brief Summary
The study is a prospective, single arm, post- marketing study. The subjects enrolled to the study will receive weekly applications of ActiGraft until complete healing or until investigator's decision that patient can no longer benefit from the study treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject is ≥18 years of age
- •Patient with a chronic lower extremity ulcer (i.e DFU, VLU, ...)
- •Ulcer duration >30 days.
- •Ulcer size decreased in less than 30% in the 14 days prior to enrollment, while treated with standard of care (or advanced treatment)
- •Subject must be willing to comply with the protocol including having blood drawn to create the ActiGraft
- •Subject can read and understand the Informed Consent form
Exclusion Criteria
- •Presence of active underlying osteomyelitis.
- •Known malignancy in the reference wound bed or margins of the wound
- •Cannot withdraw blood in the required amount technically.
- •Subject is receiving (i.e., within the past 30 days) systemic steroids (more than 10mg per day)
- •Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (within the past 30 days).
- •Subject has been treated with hyperbaric oxygen, wound VAC or Ozone gas(O3) within the past 5 days or is scheduled to receive during the study
Outcomes
Primary Outcomes
Percent of Reduction in Wound Size Over 12 Weeks
Time Frame: 4, 8, and 12 weeks
The change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage.
Secondary Outcomes
- Number of Participants Achieving a Complete re-epithelialization at 18 and 24 Weeks(18 and 24 weeks)
- Number of Participants Achieving a Complete Wound Closure at 12 Weeks(12 weeks)
- Percent of Reduction in Wound Size Over 18 and 24 Weeks.(18 and 24 weeks)
- The change in wound pain by 12 weeks(12 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest CongestionHealthy SubjectsNCT03725085Reckitt Benckiser LLC552
Completed
Not Applicable
A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision ProsthesisOsteoarthritisNCT02912351Medacta USA24
Completed
Not Applicable
Safety and Performance of the EndoFast Reliant SCP in Vaginal Wall ReinforcementPelvic Organ ProlapseNCT03516136Allium, Ltd.84
Terminated
Not Applicable
directSTIM™ Deep Brain Stimulation System Post-Market Clinical Follow-up Study on Essential TremorEssential TremorNCT05795218Aleva Neurotherapeutics SA21
Terminated
Not Applicable
ROSA® Hip System THA PMCFOsteoarthritis, HipAvascular Necrosis of HipNCT05497206Zimmer Biomet12